Posted by Michael Wonder on 15 Jun 2026
Ultomiris granted priority review in the US as treatment for adults with immunoglobulin A nephropathy
15 June 2026 - Based on I CAN Phase 3 trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks.
Alexion, AstraZeneca Rare Disease’s supplemental biologics license application for Ultomiris (ravulizumab) has been accepted and granted priority review by the US FDA for the treatment of adults with immunoglobulin A nephropathy.
